Fiche société
Immunis, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IMM02-KORAThe goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia. | Parkinson | Phase 1 | À vérifier | À vérifier | |
| IMM02-KORAThe goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia. | Parkinson | Phase 1 | À vérifier | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IMM02-KORA | Parkinson | Phase 1 | NCT07905976 | KORA-LID-1 — Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||